Drug intelligence / Profile preview

eciskafusp alfa + BCG

Development stage: Unknown
Lead developer: Roche
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Live Biotherapeutic Products → Microbiome Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Intravesical

Overview

A combination therapy of **eciskafusp alfa** and **BCG (Bacillus Calmette-Guérin)** developed for the treatment of BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC). **Eciskafusp alfa** is an experimental immunocytokine designed to target the PD-1 pathway, delivering an IL-2 variant (IL-2v) preferentially to PD-1–positive immune cells, aiming to enhance anti-tumor immunity within the bladder. **BCG** is an established intravesical immunotherapy employing live attenuated Mycobacterium bovis to stimulate a local immune response against bladder tumors. The combination is administered intravesically to maximize local immunostimulatory effects and prevent recurrence or progression in NMIBC patients unresponsive to BCG monotherapy. The combination has not received regulatory approval and is being tested for safety, tolerability, pharmacokinetics, biomarkers, pharmacodynamics, and anti-tumor activity[1][2][3][4][5][6][8].

Brand names: BCG-medac
Other names: Bacillus Calmette-GuérinBCGeciskafusp alfa + Bacillus Calmette-Guérin

Targets

PDCD1 (Programmed cell death protein 1 receptor)IL2RB (IL-2 receptor beta chain)

Beyond the preview

Go deeper on eciskafusp alfa + BCG.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eciskafusp alfa + BCG.

Explore the full profile